Q2 2026 13F · SEC CIK 310158
Merck & Co., Inc.
CorporationFiled 2026-08-07 for Q2 2026. Open the filing ↗ · All SEC filings ↗
- Reported 13F value
- $526.4M
- Reported positions
- 13
- Holdings vs S&P 500, 3 yrs
- —
- Average holding period
- 1.6 yrs
Merck & Co., Inc. is a corporation that reported 13 positions worth $526.4M in its Q2 2026 13F, filed 2026-08-07. Its largest holdings were Personalis Inc (PSNL, 35.8%), Moderna Inc (MRNA, 30.7%), Kymera Therapeutics Inc (KYMR, 16.8%).
Merck & Co., Inc. holdings all 13 positions.
Weights are shares of the filer's total reported 13F value, compared with Q1 2026. Share changes may reflect splits; weight changes also reflect price moves. A 13F shows long US-listed positions only, up to 135 days after the fact.
| Stock | % of 13F value | Share change | Reported value |
|---|---|---|---|
| PSNLPersonalis Inc | 35.8% | +0.0% | $188.2M |
| MRNAModerna Inc | 30.7% | +0.0% | $161.6M |
| KYMRKymera Therapeutics Inc | 16.8% | +0.0% | $88.5M |
| AKTSAktis Oncology Inc | 5.8% | +0.0% | $30.7M |
| EIKNEikon Therapeutics Inc | 4.1% | +0.0% | $21.7M |
| TRDAEntrada Therapeutics Inc | 2.4% | — | $12.8M |
| STROSutro Biopharma Inc | 1.7% | — | $9.0M |
| ALECAlector, Inc. | 1.4% | +0.0% | $7.1M |
| EVAXEvaxion Biotech A/s | 0.7% | — | $3.8M |
| VRDNViridian Therapeutics Inc | 0.3% | +0.0% | $1.7M |
| XLOXilio Therapeutics Inc | 0.2% | +0.0% | $1.0M |
| HURATuhura Biosciences Inc | 0.0% | +0.0% | $46K |
| NEUPNeuphoria Therapeutics Inc | 0.0% | +0.0% | $44K |
What Merck & Co., Inc. bought and sold in Q2 2026, against Q1 2026.
New positions
- TRDA Entrada Therapeutics Inc2.4% of 13F
- STRO Sutro Biopharma Inc1.7% of 13F
- EVAX Evaxion Biotech A/s0.7% of 13F
Added to
No position grew by more than 5%.
Reduced
No position shrank by more than 5%.
Sold out
- TRDA Entrada Therapeutics Incwas 6.3%
- STRO Sutro Biopharma Incwas 1.9%
- Evaxion Biotech A/swas 1.3%
- Carisma Therapeutics Incwas 0.0%
Share counts compared with the Q1 2026 13F; a split also changes share counts.
How the holdings did against the S&P 500.
- 1 year
- +196.0% /yr
- S&P 500 +11.7%
- 3 years
- —
- 5 years
- —
A portfolio of the filer's 20 largest 13F positions, weighted by value, bought the trading day after each 13F was filed and held until the next one was: what copying this filer could have earned. 13Fs show long US-listed positions only, so this is an estimate of the stock picks, not the fund's reported returns.
Reported 13F value by quarter.
| Quarter | 13F value | Positions |
|---|---|---|
| Q2 2026 | $526.4M | 13 |
| Q1 2026 | $349.4M | 14 |
| Q4 2025 | $276.3M | 12 |
| Q3 2025 | $228.0M | 13 |
| Q2 2025 | $215.6M | 13 |
| Q1 2025 | $164.3M | 12 |
| Q4 2024 | $258.0M | 13 |
Questions about Merck & Co., Inc.'s portfolio
What stocks does Merck & Co., Inc. own?
Merck & Co., Inc.'s latest 13F, for Q2 2026 and filed Aug 7, 2026, lists 13 positions worth $526.4M. The largest are Personalis Inc (PSNL) at 35.8%, Moderna Inc (MRNA) at 30.7%, Kymera Therapeutics Inc (KYMR) at 16.8%, Aktis Oncology Inc (AKTS) at 5.8% and Eikon Therapeutics Inc (EIKN) at 4.1%.
What did Merck & Co., Inc. buy last quarter?
In Q2 2026, Merck & Co., Inc. added a new position in Entrada Therapeutics Inc (TRDA), a new position in Sutro Biopharma Inc (STRO) and a new position in Evaxion Biotech A/s (EVAX), compared with its Q1 2026 filing.
What did Merck & Co., Inc. sell last quarter?
In Q2 2026, Merck & Co., Inc. sold all of Entrada Therapeutics Inc (TRDA), sold all of Sutro Biopharma Inc (STRO), sold all of Evaxion Biotech A/s and sold all of Carisma Therapeutics Inc, compared with its Q1 2026 filing.
When is Merck & Co., Inc.'s next 13F filing due?
13F filings are due 45 days after each quarter ends. Merck & Co., Inc.'s filing for the quarter ending Sep 30, 2026 is due by Nov 14, 2026; this page updates the day after it is published.